Quality assurance

Organic and Mutagenic Impurities in Pharma

The pursuit of high-quality active substances remains
paramount in the pharmaceutical industry. A critical factor in achieving this goal is meticulous control of impurity content. Evaluating impurities in pharmaceuticals is essential to guarantee both their safety and efficacy.  These unintended molecules arise during synthesis, storage, or formulation, and some may harbor potential toxicity.

Download now

Share with a colleague

Email
LinkedIn
WhatsApp

Come visit our booth at CPHI Barcelona 2023

Come to see the QbD Group at stand #3G73 at CPHI Conference in Barcelona. And after the conference…Eat & Connect with lifescience professionals at our QbD’s CPHI Networking Drink.